Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CBFB | Q13951 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31157033 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TP53CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL19170937 | 0.85 | HSD17B10 (0.51) | ALDH1A1TP53CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3969749 | 0.84 | ALDH1A1 (0.49) | ALDH1A1TP53CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL909787 | 0.83 | CBFB (0.54) | ALDH1A1TP53CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL24276142 | 0.83 | CBFB (0.49) | ALDH1A1TP53CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6958254 | 0.83 | ALDH1A1 (0.49) | ALDH1A1TP53CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL2812508 | 0.80 | ALDH1A1 (0.42) | ALDH1A1TP53CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6935068 | 0.78 | ALDH1A1 (0.54) | ALDH1A1TP53CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6526190 | 0.78 | PDE5A (0.45) | ALDH1A1CBFBPOLBPARP1PDE5A | |
| SCHEMBL1170818 | 0.78 | CBFB (0.69) | ALDH1A1TP53CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3072890-B1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | MEI PHARMA INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3072890-A1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | MEI Pharma, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2411387-B1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | VETDC INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-9108980-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150038486-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | ELANCO US INC. | 2015-02-05 | — | — | US | disclosed |
| US-8772287-B2 | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | VETDC, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20130289016-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | ELANCO US INC. | 2013-10-31 | — | — | US | disclosed |
| US-8569296-B2 | PI3K (delta) selective inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| WO-2009120094-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009120094-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-10-01 | — | — | WO | disclosed |
| EP-2061784-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-05-27 | — | — | EP | disclosed |
| EP-2057147-A1 | PYRIMIDINE DERIVATIVES | Astra Zeneca AB (SE) | 2009-05-13 | — | — | EP | disclosed |
| US-20080287431-A1 | Heterocyclic Compound and Anti-Malignant-Tumor Agent Containing the Same as Active Ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2008-11-20 | — | — | US | disclosed |
| US-20080113987-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-05-15 | — | — | US | disclosed |
| WO-2008032064-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032086-A1 | 2-BENZIMIDAZOLYL-6-MORPHOLINO-4-PHENYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| EP-1864665-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1741714-A1 | HETEROCYCLIC COMPOUND AND ANTI-MALIGNANT-TUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287431-A1 | Heterocyclic Compound and Anti-Malignant-Tumor Agent Containing the Same as Active Ingredient | TP53, RB1, VHL | ALDH1A1 2121/4885TP53 1/4885CYP3A4 4183/4885 |
| US-20140051699-A1 | PI3K (delta) SELECTIVE INHIBITORS | PIK3CD, PIK3CA, PIK3R5 | ALDH1A1 4578/4885TP53 962/4885CYP3A4 1636/4885 |
| US-20080113987-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | IL2, NFATC1, CD47 | ALDH1A1 2283/4885TP53 14/4885CYP3A4 4368/4885 |
| US-20150038486-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | ALDH1A1 318/4885TP53 94/4885CYP3A4 456/4885 |
| US-20130289016-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | ALDH1A1 318/4885TP53 94/4885CYP3A4 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.